Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Forest Namenda Clears FDA; Alzheimer Drug Shipments To Begin In December

Executive Summary

Forest is planning a slow roll-out of Namenda (memantine) after a faster-than-expected approval of the Alzheimer's agent

You may also be interested in...



Nektar Branches Out In Pain, Hails Next Generation Of Analgesics

At R&D event, company signals shift of Phase III for lead pain drug NKTR-181 to mid-2014 from earlier in the year. Nektar also featured crop of new drugs targeted at different molecular pathways, including NKTR-192, a partial agonist for acute pain, and a new kind of sodium channel blocker called NKTR-171 for neuropathy.

Reminyl Name Change Gives J&J Fresh Message For Galantamine ER Launch

Janssen's name change for its Reminyl Alzheimer's products gives the company a fresh platform for promoting the galantamine extended-release formulation approved by FDA Dec. 22

Reminyl Name Change Gives J&J Fresh Message For Galantamine ER Launch

Janssen's name change for its Reminyl Alzheimer's products gives the company a fresh platform for promoting the galantamine extended-release formulation approved by FDA Dec. 22

Related Content

UsernamePublicRestriction

Register

OM014079

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel